TrialEuropean heart journal2020

Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia.

Daniel Gaudet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.